RESUMO
One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamilton's Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanova's Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients' age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either "excellent" or "good" outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrist's choice for administering Toloxatone.
Assuntos
Depressão/tratamento farmacológico , Oxazóis/uso terapêutico , Oxazolidinonas , Adolescente , Adulto , Idoso , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , PsicometriaRESUMO
En el presente trabajo, los autores informan su experiencia sobre la utilización en 64 pacientes insonmes y deprimidos con el uso de una nueva molécula hipnótico: la Zopiclona, no emparentado químicamente con los barbitúricos ni la benzodiazepina; integra la familia química de las ciclopirrolonas. El presente estudio constituye el segundo módulo de un ensayo clínico programado para tres tramos. Este segundo tramo confronta la molécula activa (Zopiclona) versus placebo. El tercer y último módulo, reducirá la medicación antidepresiva asociada a una sola molécula activa a elección de los investigadores(AU)
RESUMO
En el presente trabajo, se exponen los resultados de la utilización de un I.M.A.O. de segunda generación (I.M.A.O. A) en el tratamiento de pacientes portadores de una depresión resistente. El fármaco utilizado es la Toloxatona, el cual se administró a una dosis promedio de 600 mg/día, repartidos en dos tomas de 400 y 200 mg en la mañana y primeras horas de la,tarde respectivamente. El ensayo se llevó sobre 66 pacientes, en los cuales la duración del tratamiento estuvo comprendida entre 3 y 6 meses para ser incluido en la evaluación. La Toloxatona se administró en todos los pacientes como único antidepresivo asociado a medicación ansiolítica o hipnótico, según los requerimientos del caso. La Toloxatona se trata de un I.M.A.O. A, reversible, competitivo, específico y selectivo, cuyo sustrato es la NA y serotonina, monoaminas implicadas en el fenómeno depresivo. Toloxatona disminuye el catabolismo intrneuronal cerebral de las aminas biógenas, permitiendo, a través de este mecanismo más fisiológico, una mayor biodisponibilidad de éstas(AU)
RESUMO
One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamiltons Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanovas Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either [quot ]excellent[quot ] or [quot ]good[quot ] outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrists choice for administering Toloxatone.
RESUMO
One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamiltons Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanovas Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either [quot ]excellent[quot ] or [quot ]good[quot ] outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrists choice for administering Toloxatone.